Education of both patients and providers will be necessary to temper expectations of cancer care treatment outcomes, according to panelists Ted Okon, BS, MBA, executive director of the Community Oncology Alliance, Debra Patt, MD, MPH, partner at Texas Oncology, and Stacie Dusetzina, PhD, assistant professor at the University of North Carolina, Chapel Hill.
%jwplayer%
Education of both patients and providers will be necessary to temper expectations of cancer care treatment outcomes, according to panelists Ted Okon, BS, MBA, executive director of the Community Oncology Alliance, Debra Patt, MD, MPH, partner at Texas Oncology, and Stacie Dusetzina, PhD, assistant professor at the University of North Carolina, Chapel Hill.
Dr Dusetzina, an epidemiologist, said that discussing risk to patients can be difficult, as can explaining that sometimes getting high value care might mean forgoing treatments that have little benefit. Furthermore, patients equate high cost with high value, which isn’t always the case.
“We sort of have to change how society thinks about cancer treatment and I think actually having better transparency and being better educators … to educate society will help in that endeavor,” Dr Patt said.
Mr Okon also expressed repeated concern over the “corporatization” of cancer care, which has led to “bad medicine.”
“We have to realize that [cancer care] also big business,” he said.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen